Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's What You Should Know

Milestone Pharmaceuticals (MIST) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. For the fiscal year ending December 2024, this biotechnology company is expected to earn -$1.13 per share, which is a change of 18.7% from the year-ago reported number. Most Powerful Force Impacting Stock Prices The change in a company's future earnings ...